$CYTH
Cyclo Therapeutics, Inc. Stock $cyth

$cyth Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000143774924008181 Filed on March 18, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$202.5K	$311.4K	$1.076M
YoY Change	32.83%	66.7%	-21.76%
Cost Of Revenue	$14.19K	$20.42K	$98.46K
YoY Change	23.93%	22.94%	-34.34%
Gross Profit	$190.6K	$291.0K	$992.0K
YoY Change	35.23%	70.97%	-19.07%
Gross Profit Margin	94.16%	93.44%	92.16%
Selling, General & Admin	$2.450M	$1.784M	$6.827M
YoY Change	40.38%	-9.11%	-12.8%
% of Gross Profit	1285.15%	613.22%	688.18%
Research & Development	$2.845M	$4.144M	$14.18M
YoY Change	-16.26%	30.12%	57.58%
% of Gross Profit	1492.7%	1424.27%	1429.56%
Depreciation & Amortization	$2.177K	$4.820K	$19.28K
YoY Change	-54.82%	-1.03%	-1.05%
% of Gross Profit	1.14%	1.66%	1.94%
Operating Expenses	$2.845M	$5.934M	$14.18M
YoY Change	-16.26%	15.14%	57.58%
Operating Profit	-$5.121M	-$5.643M	-$20.05M
YoY Change	2.28%	13.24%	28.35%
Interest Expense	$237.6K	$110.00	-$7.250K
YoY Change	475040.0%	-95.56%	-158.14%
% of Operating Profit
Other Income/Expense, Net	$778.0K		-$7.245K
YoY Change	1655217.02%		-158.08%
Pretax Income	-$4.343M	-$5.642M	-$20.06M
YoY Change	-13.26%	13.29%	29.81%
Income Tax	$0.00		$0.00
% Of Pretax Income
Net Earnings	-$4.343M	-$5.642M	-$20.06M
YoY Change	-13.26%	13.29%	29.81%
Net Earnings / Revenue	-2145.25%	-1811.95%	-1863.36%
Basic Earnings Per Share	-$0.15		-$1.23
Diluted Earnings Per Share	-$0.15	-$0.25	-$1.23
COMMON SHARES
Basic Shares Outstanding	28.72M	22.73M	16.33M
Diluted Shares Outstanding

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.995M	$9.247M	$9.247M
YoY Change	227.28%	499.1%	499.1%
Cash & Equivalents	$2.995M	$9.247M	$9.247M
Short-Term Investments
Other Short-Term Assets	$3.261M	$2.695M	$2.695M
YoY Change	20.66%	16.88%	16.88%
Inventory	$242.5K	$254.4K	$254.4K
Prepaid Expenses
Receivables	$71.32K	$122.4K	$122.4K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$6.570M	$12.32M	$12.32M
YoY Change	64.52%	196.21%	196.21%
LONG-TERM ASSETS
Property, Plant & Equipment	$24.34K	$38.33K	$929.3K
YoY Change	-51.67%	-30.54%	1540.1%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$593.8K	$929.3K	$929.3K
YoY Change	472.29%	1540.16%	1540.39%
TOTAL ASSETS
Total Short-Term Assets	$6.570M	$12.32M	$12.32M
Total Long-Term Assets	$593.8K	$929.3K	$929.3K
Total Assets	$7.164M	$13.25M	$13.25M
YoY Change	74.85%	214.28%	214.28%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.671M	$4.857M	$5.775M
YoY Change	-18.11%	39.53%	65.9%
Accrued Expenses	$1.746M	$1.011M	$2.694M
YoY Change	10187.8%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$6.536M	$8.468M	$8.468M
YoY Change	45.27%	143.29%	143.29%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$17.51K	$22.48K	$22.48K
YoY Change	-52.07%
Total Long-Term Liabilities	$17.51K	$22.48K	$22.48K
YoY Change	-52.07%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.536M	$8.468M	$8.468M
Total Long-Term Liabilities	$17.51K	$22.48K	$22.48K
Total Liabilities	$6.554M	$8.491M	$8.491M
YoY Change	44.48%	143.93%	143.93%
SHAREHOLDERS EQUITY
Retained Earnings	-$88.20M	-$83.86M
YoY Change	28.19%	31.44%
Common Stock	$0.00	$2.856K
YoY Change	-100.0%	236.4%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$610.0K	$4.757M	$4.757M
YoY Change
Total Liabilities & Shareholders Equity	$7.164M	$13.25M	$13.25M
YoY Change	74.85%	214.28%	214.28%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$4.343M	-$5.642M	-$20.06M
YoY Change	-13.26%	13.29%	29.81%
Depreciation, Depletion And Amortization	$2.177K	$4.820K	$19.28K
YoY Change	-54.82%	-1.03%	-1.05%
Cash From Operating Activities	-$6.182M	-$4.295M	-$16.19M
YoY Change	41.46%	56.36%	7.08%
INVESTING ACTIVITIES
Capital Expenditures		$2.420K	$2.420K
YoY Change			-83.96%
Acquisitions
YoY Change
Other Investing Activities		$0.00	$0.00
YoY Change			-100.0%
Cash From Investing Activities		-$2.420K	-$2.420K
YoY Change			-106.34%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$9.739M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$69.28K	11.74M	$23.89M
YoY Change	-101.85%		352373.0%
NET CHANGE
Cash From Operating Activities	-$6.182M	-4.295M	-$16.19M
Cash From Investing Activities		-2.420K	-$2.420K
Cash From Financing Activities	-$69.28K	11.74M	$23.89M
Net Change In Cash	-$6.251M	7.445M	$7.703M
YoY Change	895.06%	-371.04%	-151.12%
FREE CASH FLOW
Cash From Operating Activities	-$6.182M	-$4.295M	-$16.19M
Capital Expenditures		$2.420K	$2.420K
Free Cash Flow		-$4.297M	-$16.19M
YoY Change		56.45%	6.99%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	us-gaap	Professional Fees ProfessionalFees	1943757	usd
CY2022	us-gaap	Professional Fees ProfessionalFees	2417017	usd
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0000922247
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023	us-gaap	Sublease Income SubleaseIncome	0	usd
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	pure
CY2023Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	0	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	17225521	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	28715740
CY2023	dei	Auditor Name AuditorName	WithumSmith+Brown, PC
CY2023	dei	Auditor Location AuditorLocation	East Brunswick, New Jersey
CY2023	dei	Auditor Firm AuditorFirmId	100
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9246592	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1543418	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	10272	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	10272	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	122379	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	54991	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	254352	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	254491	usd
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	384889	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	101135	usd
CY2023Q4	ctdh	Prepaid Expenses Current Excluding Prepaid Insurance PrepaidExpensesCurrentExcludingPrepaidInsurance	2310045	usd
CY2022Q4	ctdh	Prepaid Expenses Current Excluding Prepaid Insurance PrepaidExpensesCurrentExcludingPrepaidInsurance	2204520	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	12318257	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	4158555	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	38332	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	55188	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	890949	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1470	usd
CY2023Q4	us-gaap	Assets Assets	13247538	usd
CY2022Q4	us-gaap	Assets Assets	4215213	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1010631	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	0	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	7457416	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	3480669	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	8468047	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3480669	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	22484	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	22484	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	0	usd
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	20000000
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	28556072
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8481848
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8481848
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	2856	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	849	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	88610832	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	64533074	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-83856681	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-63799379	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	4757007	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	734544	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	13247538	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4215213	usd
CY2022	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	1375760	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	14181769	usd
CY2023	ctdh	Repairs And Maintenance RepairsAndMaintenance	14091	usd
CY2022	ctdh	Repairs And Maintenance RepairsAndMaintenance	11019	usd
CY2023	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	1161094	usd
CY2022	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	1025635	usd
CY2023	us-gaap	Noninterest Expense Directors Fees NoninterestExpenseDirectorsFees	335268	usd
CY2022	us-gaap	Noninterest Expense Directors Fees NoninterestExpenseDirectorsFees	394009	usd
CY2023	us-gaap	Depreciation Nonproduction DepreciationNonproduction	19276	usd
CY2022	us-gaap	Depreciation Nonproduction DepreciationNonproduction	19481	usd
CY2023	ctdh	Freight And Shipping FreightAndShipping	3902	usd
CY2022	ctdh	Freight And Shipping FreightAndShipping	13060	usd
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	10272	usd
CY2023	us-gaap	Costs And Expenses CostsAndExpenses	21042095	usd
CY2022	us-gaap	Costs And Expenses CostsAndExpenses	16858717	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-20050057	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-15621886	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-7245	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	12474	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-20057302	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-15450888	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-20057302	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-15450888	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.23
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.83
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16329713
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8439177
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	15671863	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	354056	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-15450888	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	734544	usd
CY2023	ctdh	Stock Issued During Period Value Common Stock And Prefunded Warrants StockIssuedDuringPeriodValueCommonStockAndPrefundedWarrants	9739040	usd
CY2023	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	8806238	usd
CY2023	ctdh	Stock Issued During Period Value New Issues Warrants StockIssuedDuringPeriodValueNewIssuesWarrants	2407849	usd
CY2023	ctdh	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	2388245	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1478	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	390108	usd
CY2023	ctdh	Apic Merger Recapitalization Option Increase For Cost Recognition APICMergerRecapitalizationOptionIncreaseForCostRecognition	2009	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-20057302	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	4757007	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-20057302	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-15450888	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	19276	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	19481	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-0	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	158524	usd
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	10272	usd
CY2023	us-gaap	Inventory Write Down InventoryWriteDown	52922	usd
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	0	usd
CY2023	ctdh	Sharebased Compensation Employees SharebasedCompensationEmployees	39617	usd
CY2022	ctdh	Sharebased Compensation Employees SharebasedCompensationEmployees	15750	usd
CY2023	ctdh	Sharebased Compensation Nonemployees SharebasedCompensationNonemployees	305181	usd
CY2022	ctdh	Sharebased Compensation Nonemployees SharebasedCompensationNonemployees	143763	usd
CY2023	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	392117	usd
CY2022	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	354056	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	67388	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-427850	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	52783	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	27054	usd
CY2023	ctdh	Increase Decrease Prepaid Clinical Expenses IncreaseDecreasePrepaidClinicalExpenses	105525	usd
CY2022	ctdh	Increase Decrease Prepaid Clinical Expenses IncreaseDecreasePrepaidClinicalExpenses	189669	usd
CY2023	us-gaap	Increase Decrease In Prepaid Insurance IncreaseDecreaseInPrepaidInsurance	-41201	usd
CY2022	us-gaap	Increase Decrease In Prepaid Insurance IncreaseDecreaseInPrepaidInsurance	58889	usd
CY2023	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-2037	usd
CY2022	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-0	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	3245621	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-200389	usd
CY2023	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	3872276	usd
CY2022	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	336647	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16185026	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-15114241	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2420	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	15086	usd
CY2023	us-gaap	Payments For Proceeds From Loans Receivable PaymentsForProceedsFromLoansReceivable	-0	usd
CY2022	us-gaap	Payments For Proceeds From Loans Receivable PaymentsForProceedsFromLoansReceivable	-53256	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2420	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	38170	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	9739040	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2023	ctdh	Proceeds From Merger Recapitalization ProceedsFromMergerRecapitalization	10042488	usd
CY2022	ctdh	Proceeds From Merger Recapitalization ProceedsFromMergerRecapitalization	0	usd
CY2023	us-gaap	Payments Of Merger Related Costs Financing Activities PaymentsOfMergerRelatedCostsFinancingActivities	688480	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1478	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
CY2023	ctdh	Proceeds From Warrants Sold ProceedsFromWarrantsSold	2407849	usd
CY2023	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	2388245	usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	usd
CY2023	ctdh	Proceeds From Issuance Repayments Of Longterm Debt ProceedsFromIssuanceRepaymentsOfLongtermDebt	0	usd
CY2022	ctdh	Proceeds From Issuance Repayments Of Longterm Debt ProceedsFromIssuanceRepaymentsOfLongtermDebt	-8159	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	23890620	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6778	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	7703174	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-15069293	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1543418	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	16612711	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	9246592	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1543418	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	10056	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2023	us-gaap	Stock Issued1 StockIssued1	344798	usd
CY2022	us-gaap	Stock Issued1 StockIssued1	159513	usd
CY2023	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1	406171	usd
CY2022	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1	0	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-20057302	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-15450888	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-83856681	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16185026	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9246592	usd
CY2023Q4	ctdh	Working Capital Deficit WorkingCapitalDeficit	3850210	usd
CY2023Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	9247000	usd
CY2022Q1	us-gaap	Accounts Receivable Net AccountsReceivableNet	493000	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	10300	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	10300	usd
CY2022Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	52900	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">(q) USE OF ESTIMATES––The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions, including regarding contingencies, that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company’s most significant estimates relate to inventory obsolescence, stock-based compensation, warrant liability valuation, fair value of warrants issued, assumed liabilities associated with Merger (see Note 12), and allowance for credit losses. Although management bases its estimates on historical experience and assumptions that are believed to be reasonable under the circumstances, actual results could significantly differ from these estimates.<b> </b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2023	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	1076405	usd
CY2022	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	1375760	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	159147	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	156727	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	120815	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	101539	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	38332	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	55188	usd
CY2023	us-gaap	Depreciation Depreciation	19276	usd
CY2022	us-gaap	Depreciation Depreciation	19481	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4856530	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2233894	usd
CY2023Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	1590776	usd
CY2022Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	902614	usd
CY2023Q4	ctdh	Accrued Board Expense Current AccruedBoardExpenseCurrent	92110	usd
CY2022Q4	ctdh	Accrued Board Expense Current AccruedBoardExpenseCurrent	72125	usd
CY2023Q4	us-gaap	Deposit Liability Current DepositLiabilityCurrent	243742	usd
CY2022Q4	us-gaap	Deposit Liability Current DepositLiabilityCurrent	0	usd
CY2023Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	487402	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	0	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	186856	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	272036	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	7457416	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	3480669	usd
CY2023Q4	ctdh	Operating Lease Right Of Usse Asset Amortization OperatingLeaseRightOfUsseAssetAmortization	17242	usd
CY2022Q4	ctdh	Operating Lease Right Of Usse Asset Amortization OperatingLeaseRightOfUsseAssetAmortization	66552	usd
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	28353	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	16166	usd
CY2023	ctdh	Payments Of Cash For Amounts Included In Measurement Of Lease Liabilities PaymentsOfCashForAmountsIncludedInMeasurementOfLeaseLiabilities	17000	usd
CY2022	ctdh	Payments Of Cash For Amounts Included In Measurement Of Lease Liabilities PaymentsOfCashForAmountsIncludedInMeasurementOfLeaseLiabilities	19800	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P0Y8M19D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P0Y29D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.03	pure
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.06	pure
CY2023Q4	us-gaap	Lessor Operating Lease Payments To Be Received Next Twelve Months LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths	1390024	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1020604	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	21590	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1804	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1043998	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	10883	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1033115	usd
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	20000000
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000
CY2021Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2048186
CY2022	ctdh	Class Of Warrant Or Right Issued During Period ClassOfWarrantOrRightIssuedDuringPeriod	0
CY2022	ctdh	Class Of Warrant Or Right Exercised During Period ClassOfWarrantOrRightExercisedDuringPeriod	-0
CY2022	ctdh	Class Of Warrant Or Right Expired During Period ClassOfWarrantOrRightExpiredDuringPeriod	2340
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2045846
CY2023	ctdh	Class Of Warrant Or Right Issued During Period ClassOfWarrantOrRightIssuedDuringPeriod	18825700
CY2023	ctdh	Class Of Warrant Or Right Exercised During Period ClassOfWarrantOrRightExercisedDuringPeriod	5037993
CY2023	ctdh	Class Of Warrant Or Right Expired During Period ClassOfWarrantOrRightExpiredDuringPeriod	87707
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	15745846
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	15745846
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2023Q4	ctdh	Valuation Allowance Percentage ValuationAllowancePercentage	1	pure
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	49807000	usd
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	49807000	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	6950000	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	1659000	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	5464000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	12624000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	10761000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	6950000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	10354000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Impairment Losses DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses	3000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Impairment Losses DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses	19000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	68000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	45000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	167000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	105000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	242000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	245000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Legal Settlements DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements	95000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Legal Settlements DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements	0	usd
CY2023Q4	ctdh	Deferred Tax Assets Right Of Use Liabilities DeferredTaxAssetsRightOfUseLiabilities	262000	usd
CY2022Q4	ctdh	Deferred Tax Assets Right Of Use Liabilities DeferredTaxAssetsRightOfUseLiabilities	0	usd
CY2023Q4	ctdh	Deferred Tax Assets Capitalized Research And Development DeferredTaxAssetsCapitalizedResearchAndDevelopment	4646000	usd
CY2022Q4	ctdh	Deferred Tax Assets Capitalized Research And Development DeferredTaxAssetsCapitalizedResearchAndDevelopment	1642000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	24827000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	23167000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	230000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	4000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	3000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	4000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	227000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	-0	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	230000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	4000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.04	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.03	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.01	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.17	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.15	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.01	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.03	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.08	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.36	pure
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	6950000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	6950000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2023	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	66505	usd
CY2022	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	61168	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments	0	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	222700
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.45
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y8M12D
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	226746
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.18
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	0
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	23800
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	425646
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.17
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y10M24D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	459281
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.91
CY2023	ctdh	Share Based Compensation Arrangement By Share Based Payment Award Options Assumed In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInPeriodGross	108875
CY2023	ctdh	Share Based Compensation Arrangements By Share Based Payment Award Options Assumed In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAssumedInPeriodWeightedAverageExercisePrice	2.96
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1155
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.28
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	0
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	92827
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	3.15
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	899820
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.12
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y8M12D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	465566
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	3.68
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0	usd
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y8M12D
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	862605	usd
CY2023	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P7Y8M12D
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-20057302	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-15450888	usd
CY2023	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	16329713
CY2022	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	8439177
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.23
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.83

Files In Submission

Name	View Source	Status
0001437749-24-008181-index-headers.html	Edgar Link	pending
0001437749-24-008181-index.html	Edgar Link	pending
0001437749-24-008181.txt	Edgar Link	pending
0001437749-24-008181-xbrl.zip	Edgar Link	pending
a01.jpg	Edgar Link	pending
a02.jpg	Edgar Link	pending
a03.jpg	Edgar Link	pending
a04.jpg	Edgar Link	pending
a05.jpg	Edgar Link	pending
a06.jpg	Edgar Link	pending
a07.jpg	Edgar Link	pending
a08.jpg	Edgar Link	pending
a09.jpg	Edgar Link	pending
a10.jpg	Edgar Link	pending
a11.jpg	Edgar Link	pending
a12.jpg	Edgar Link	pending
a13.jpg	Edgar Link	pending
a14.jpg	Edgar Link	pending
a15.jpg	Edgar Link	pending
a16.jpg	Edgar Link	pending
a17.jpg	Edgar Link	pending
a18.jpg	Edgar Link	pending
a19.jpg	Edgar Link	pending
ctdh-20231231.xsd	Edgar Link	pending
ctdh20231231c_10k.htm	Edgar Link	pending
ex_637148.htm	Edgar Link	pending
ex_637149.htm	Edgar Link	pending
ex_637150.htm	Edgar Link	pending
ex_637720.htm	Edgar Link	pending
ex_638335.htm	Edgar Link	pending
ex_638336.htm	Edgar Link	pending
ex_638664.htm	Edgar Link	pending
ex_638664img001.jpg	Edgar Link	pending
ex_638664img002.jpg	Edgar Link	pending
ex_640707.htm	Edgar Link	pending
ex_640768.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image01.jpg	Edgar Link	pending
image02.jpg	Edgar Link	pending
image03.jpg	Edgar Link	pending
image04.jpg	Edgar Link	pending
image05.jpg	Edgar Link	pending
ctdh-20231231_cal.xml	Edgar Link	unprocessable
ctdh-20231231_def.xml	Edgar Link	unprocessable
ctdh-20231231_lab.xml	Edgar Link	unprocessable
ctdh-20231231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
ctdh20231231c_10k_htm.xml	Edgar Link	completed
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CYTH
Cyclo Therapeutics, Inc. Stock $cyth

2024 Q1 Form 10-K Financial Statement

#000143774924008181 Filed on March 18, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CYTH Cyclo Therapeutics, Inc. Stock $cyth

2024 Q1 Form 10-K Financial Statement

#000143774924008181 Filed on March 18, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CYTH
Cyclo Therapeutics, Inc. Stock $cyth